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https://doi.org/10.1016/j.celrep.2021.108852SUMMARYAs the global COVID-19 pandemic progresses, it is paramount to gain knowledge on adaptive immunity to
SARS-CoV-2 in children to define immune correlates of protection upon immunization or infection. We
analyzed anti-SARS-CoV-2 antibodies and their neutralizing activity (PRNT) in 66 COVID-19-infected children
at 7 (±2) days after symptom onset. Individuals with specific humoral responses presented faster virus clear-
ance and lower viral load associated with a reduced in vitro infectivity. We demonstrated that the frequencies
of SARS-CoV-2-specific CD4+CD40L+ T cells and Spike-specific B cells were associated with the anti-SARS-
CoV-2 antibodies and themagnitude of neutralizing activity. The plasma proteome confirmed the association
between cellular and humoral SARS-CoV-2 immunity, and PRNT+ patients show higher viral signal transduc-
tion molecules (SLAMF1, CD244, CLEC4G). This work sheds lights on cellular and humoral anti-SARS-CoV-2
responses in children, which may drive future vaccination trial endpoints and quarantine measures policies.INTRODUCTION
The severe acute respiratory syndrome-coronavirus-2 (SARS-
CoV-2), first emerged inWuhan, China in December 2019 (Huang
et al., 2020), and spread to Europe and, in particular, the northern
regions of Italy in the beginning of February 2020. On March 12,
2020, with >100 countries reporting an increasing number of
cases, the World Health Organization (WHO) declared a global
pandemic (World Health Organization, 2020). Despite the unprec-
edented scientific effort, the impact of antigen (Ag)-specific
cellular immune responses (Altmann and Boyton, 2020) and
neutralizing antibodies (Zhang et al., 2020) is only partially known,
particularly in children. Antibody (Ab)-mediated neutralizing activ-
ity was shown 21 days after infection onset in theminority (2 of 45)This is an open access article under the CC BY-Nof specificmonoclonal Abs isolated fromAg-specific B cells (Sey-
doux et al., 2020) of an infected adult. In particular, themost effec-
tiveAb showeda specific binding for the receptor-binding domain
(RBD) and was able to prevent viral entry (Seydoux et al., 2020).
The contribution of SARS-CoV-2-specific CD4+ T cells to the pro-
duction of effective neutralizing Abs has been recently shown in
adults (Grifoni et al., 2020; Meckiff et al., 2020; Weiskopf et al.,
2020), but no data on its impact on the virus nor its association
to Ag-specific B cells have been shown.
In the context of pediatric infection, data on the SARS-CoV-2
specific immunity are still scarce. Few studies have shown that
children are able to develop a robust neutralizing Ab (NAb)
response after infection (Liu et al., 2020; Yonker et al., 2020;
Zhang et al., 2020). However, SARS-CoV-2-specific T andCell Reports 34, 108852, March 16, 2021 ª 2021 The Author(s). 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Patients’ characteristics
SARS-CoV-2+ (N = 66) SARS-
CoV-2





















































































































(8/24/16) (7/14/8) NA n.s.
Continuous data were presented as means ± SDs. Non-parametric
Mann-Whitney test was used for comparisons. When data were missing,
the total N was clearly indicated. Symptomatology: 0 = asymptomatic;
1 = mild ; 2 = moderate, according to WHO classification (https://www.
who.int/publications/i/item/clinical-management-of-covid-19). CRP,
C-reactive protein; Hb, hemoglobin; NA, not applicable; n.s., not signifi-
cant; SD, standard deviation; WBC, white blood cell.
aDuration of symptoms was calculated as the number of days between
symptoms onset and date of analysis; for asymptomatic patients, the
symptom onset of the family member or direct contact who tested posi-
tive for SARS-CoV-2 was used.
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OPEN ACCESSB cell immunity needs to be defined in relation to NAbs and viral
control. Overall, children experience a milder clinical course of
coronavirus disease 2019 (COVID-19) as compared to adults
(Gupta et al., 2020), and it is paramount to define the impact of
adaptive SARS-CoV-2-specific immunity on viral spread and
clinical course in pediatric cases (Brodin, 2020).2 Cell Reports 34, 108852, March 16, 2021In this work, we aim to define the humoral and cellular re-
sponses in SARS-CoV-2-infected children. We investigated the
NAb activity in SARS-CoV-2-infected children and its impact
on the viral load in nasopharyngeal (NP) swabs. We further
explored Ag-specific T and B cells defined as CD4+CD40L+
and SARS-CoV-2 Spike (S1+S2)-positive switched B cells.
Finally, we provided a comprehensive proteomic profile focusing
on the differences between SARS-CoV-2-infected individuals
with differential neutralizing ability.
RESULTS
Clinical and standard laboratory profile of SARS-CoV-2-
infected children compared to SARS-CoV-2
Standard laboratory analysis and demographic characteristics
were explored to define differences among SARS-CoV-2-in-
fected children (SARS-CoV-2+, n = 66), and those admitted
for the clinical suspicion of SARS-CoV-2 but tested negative
by both virological and serological methods (SARS-CoV-2,
n = 11). By study design, we aimed to study humoral and
cellular responses in SARS-CoV-2+ children on samples
collected 7 days (± 2 days) after symptoms onset (mean overall
cohort = 6.63 days). For asymptomatic patients, the symptom
onset of the family member or direct contact who tested posi-
tive for SARS-CoV-2 was used. In Table 1, we further stratified
the cohort according to the presence of NAbs measured by the
plaque reduction neutralization test (PRNT). Overall, 37/66
(56%, PRNT+) developed NAbs, whereas 29/66 (44%, PRNT)
did not. No significant differences in terms of age, gender, and
lymphocyte count was found between PRNT+ and PRNT and
SARS-CoV-2. Higher white blood cell (WBC) count was
found in SARS-CoV-2 compared to PRNT+ (p = 0.007) and
PRNT (p = 0.041), as well as a trend for higher hemoglobin
(Hb) in PRNT versus PRNT+ (p = 0.04). This result is in
line with the higher C-reactive protein (CRP) levels found in
SARS-CoV-2 compared to both PRNT+ and PRNT (p <
0.0001 and p = 0.002, respectively; Table 1), supporting
an alternative infectious/inflammatory condition in SARS-
CoV-2. The development of Abs was not associated with
age and did not differ between age groups: infant (<1 year),
toddler (1–2 years), preschool (3–5 years), school age (6–12
years), and teenagers (13–17 years) (Table 1) . At admission,
PRNT+ and PRNT patients did not differ in regard to disease
severity, which can be noted as 0 = asymptomatic, 1 = mild,
and 2 = moderate, according to the WHO classification
(https://www.who.int/publications/i/item/clinical-management-of-
covid-19) (Tables 1 and S1).
SARS-CoV-2-specific immunoglobulin G (IgG) and Ab
neutralizing activity associate with faster virus
clearance, lower viral load, and reduced in vitro
infectivity
In NP, we evaluated the viral load by droplet digital PCR (ddPCR)
andRT-PCR inassociationwithSARS-CoV-2humoral responses.
Our data show an inverse correlation between viral load in NP and
both S1/S2 SARS-CoV-2 IgG (p = 0.0005; r= 0.69) (Figure 1A)
and PRNT (p < 0.0001; r= 0.67) (Figure 1B). In vitro infectivity,
measured in foci forming units (FFUs), showed an inverse
Figure 1. SARS-CoV-2-specific IgG and Ab
neutralization activities were inversely
associated with viral load, virus clearance,
and infectivity
(A–E) Correlation plots show in (A) association
between ddPCR and SARS-CoV-2 IgG titers
(n = 21); (B) association between ddPCR and
PRNT (n = 29); (C) association between infectivity
in vitro (FFU) and SARS-CoV-2 IgG titers (n = 17);
(D) association between infectivity in vitro (FFU)
and PRNT (n = 24); and (E) association between
SARS-CoV-2 IgG and SARS-CoV-2 RNA copies/
mL (AUC) (n = 16). Solid lines define linear
regression, and grey areas show 95% confidence
interval.
Non-parametric Spearman correlation was used
in (A)–(E). Non-parametric Mann-Whitney test was
used in (F), means with SD are shown in the plot.
AUC, area under the curve; ddPCR, digital droplet
PCR; FFU, foci forming unit; NP, nasopharyngeal
swab. Light purple triangles, SARS-CoV-2 IgG+;
light green triangles, SARS-CoV-2 IgG; light




OPEN ACCESScorrelationwithbothS1/S2SARS-CoV-2 IgG (p=0.003;r=0.67)
(Figure 1C) andPRNT (p = 0.023; r=0.46) (Figure 1D). Longitudi-
nal analysis confirmed the impact of humoral responses on virus
clearance. We calculated the area under the curve (AUC) of the
viral load from NP collected every 48 h up to undetectable viral
load, and we found an inverse correlation with SARS-CoV-2 Ab
(p = 0.031; r= 0.54) (Figure 1E). We further compared the levels
ofSARS-CoV-2 viral load in seropositive and seronegative individ-
uals. Our results show a significantly higher viral load in seroneg-
ative patients expressed in terms of both S1/S2 SARS-CoV-2
IgG (p = 0.003) and PRNT (p = 0.0007) (Figure 1F). Overall, these
data confirm the role of SARS-CoV-2-specific humoral responses
incontrolling virus replication, expected infectivity, andvirusclear-
ance. As previously reported (GeurtsvanKessel et al., 2020), we
found S1/S2 SARS-CoV-2 IgG levels to positively correlate with
PRNT titers (p = 0.0002; r= 0.65) (Figure S1).C
SARS-CoV-2-specific B cells
positively associate with SARS-
CoV-2-specific IgG and PRNT
The B cell compartment and the fre-
quency of SARS-CoV-2-specific B cells
were analyzed by fluorescence-acti-
vated cell sorting (FACS) using an
in-house fluorescently labeled probe
expressing S1+S2 SARS-CoV-2 pro-
teins (gating strategy in Figures 2A
and S2A). We analyzed the SARS-
CoV-2-specific IgD-CD27+ switched B
cells (Figure 2A) and found a positive
association with both S1/S2 SARS-
CoV-2 IgG (p = 0.003; r= 0.54) and
PRNT (p = 0.008; r= 0.49) (not shown).
This association was also confirmed
when Ag-specific B cells were re-analyzed in SARS-CoV-2+ children stratified by their serolog-
ical status. A higher frequency of Ag-specific B cells was
found in seropositive compared to seronegative SARS-CoV-
2 children (p = 0.001) (Figure 2B). We also observed a
trend for a higher frequency of Ag-specific B cells in PRNT+
(p = 0.052) (Figure 2C).
We further explored the standard B cell phenotype and found
no differences in terms of total B cells (CD19+CD10 B cells) in
PRNT+ compared to PRNT (Figure S2B). B cell memory
compartment analysis, according to the expression of IgD and
CD27, showed a higher frequency of switched memory B cells
in PRNT+ compared to PRNT (Figure S2C) despite no differ-
ences in age between the groups. According to the expression
of CD21 and CD27, a lower frequency of tissue-like memory
(TLM) B cells resulted in PRNT+ compared to PRNT
(Figure S2D).ell Reports 34, 108852, March 16, 2021 3
Figure 2. SARS-CoV-2-specific B cells are
positively associated with anti-SARS-CoV-
2 IgG and Ab neutralization activity
(A) Gating strategy for antigen-specific B cells.
(B and C) SARS-CoV-2 Mann-Whitney test (n =
28); means and SD are shown in the plots.
Light purple triangles, SARS-CoV-2 IgG+; light
green triangles, SARS-CoV-2 IgG; light purple




OPEN ACCESSSARS-CoV-2-specific CD4 T cells are positively
associated with PRNT
To further characterize the immunological features of patients
with differential neutralization activity against SARS-CoV-2, we
investigated CD3+CD4+ general phenotype and frequency of
SARS-CoV-2-specific CD4 T cells (gating strategy in Figures
3A and S3A). Ag-specific CD4 T cells were defined through the
analysis of CD40L after in vitro stimulation with SARS-CoV-2
Ags using a previously validated methodology (de Armas et al.,
2017; Cotugno et al., 2017, 2020a, 2020b; Chattopadhyay
et al., 2006). Pairwise correlation analysis showed a positive as-
sociation between Ag-specific T cells and Ab-mediated neutral-
ization activity (p = 0.039; r= 0.39) (not shown). Furthermore,
PRNT+ revealed a higher frequency of SARS-CoV-2-specific
T cells compared to PRNT (p = 0.03; Figure 3C). No differences
in terms of Ag-specific T cells emerged in patients with differen-
tial SARS-CoV-2 IgG serostatus. Overall, these results may sug-
gest that Ag-specific T cells may correlate with NAb classes4 Cell Reports 34, 108852, March 16, 2021other than IgG such as IgA in turn having
a higher correlation with mucosal and tis-
sue resident antibodies (Hsueh et al.,
2004).
We also explored the standard T cell
phenotype, and we could benefit from a
cohort of healthy age- and gender-
matched children examined in the pre-
COVID-19 era. Whereas no differences
emerged in terms of total CD3+CD4+ be-
tween PRNT+, PRNT, and SARS-
CoV-2, both SARS-CoV-2+ groups
(PRNT+ and PRNT) showed a higher
CD3+CD4+ frequency compared to
healthy control (HC) (p = 0.001 and
p = 0.017, respectively) (Figure S3B).
Maturational subsets were analyzed ac-
cording to the surface expression of
CD45RO and CD27. PRNT+ expressed a
significantly lower frequency of terminally
differentiated effector memory (TEMRA)
T cells compared to both PRNT and
SARS-CoV-2 patients (Figure S3C).
Through the expression of CXCR5 on live
CD3+CD4+CD45RO+CD27+ central mem-
ory T cells, we investigated peripheral
follicular T helper cells (pThf). Our analysis
showed a lower frequency of pThf in bothPRNT+ and PRNT patients compared to HC (p = 0.004 and
p = 0.004, respectively) (Figure S3D). We also found that PRNT
had lower pTfh compared to SARS-CoV-2 children (p = 0.040)
(Figure 3D), suggesting how the frequency of this subset can
play a crucial role in the context of SARS-CoV-2 infection.
Proteomics characteristics of SARS-CoV-2 patients
with differential neutralizing activity
We explored plasma proteomic correlates of immune responses
in patients with SARS-CoV-2 neutralization activity. We could
benefit from previous data generated with the Olink platform
on plasma samples collected in our cohort at diagnosis and
before treatment initiation (Consiglio et al., 2020). We obtained
121 unique plasma proteins using 2 Olink panels associated
with inflammation pathways filtering out proteins with >30%
measurements below the threshold of detection. Principal-
component analysis (PCA) analyzed for proteomics revealed
no clear clusters between PRNT+ and PRNT (data not shown),
Figure 3. SARS-CoV-2-specific CD4 T cells
are positively associated with SARS-CoV-
2-specific IgG and Ab-neutralization activity
(A) Gating strategy for antigen-specific T cells
(CD40L+). Left-side panels show CD40L+CD4+
T cells for unstimulated (UN) and stimulated (STIM)
samples in a healthy control (HC). Right-side
panels show the same conditions for a SARS-
CoV-2-infected patient.
(B and C) Twenty-eight patients split according to
SARS-CoV-2 IgG (B) and PRNT (C) were
compared by the Mann-Whitney test; means and
SD are shown in the plots.
Light purple triangles, SARS-CoV-2 IgG+; light
green triangles, SARS-CoV-2 IgG; light purple




OPEN ACCESSsuggesting a similar pro-inflammatory pattern in both SARS-
CoV-2 groups, which were similar overall in terms of symptom-
atology (see Tables 1 and S1). The full dataset of correlations
is available in Figure S4.
We further assessed whether the presence of neutralizing ac-
tivity was associated with the differential expression of specific
plasma factors. Two different proteins belonging to the signaling
lymphocytic activation molecule pathway (SLAMF1) (Figure 4A)
and CD244 (Figure 4B) were significantly higher in PRNT+
compared to PRNT (p = 0.002 and p = 0.03, respectively).
Such molecules were previously shown to be present on acti-
vated T and B cells and to be essential receptor and signaling
transductors for viral entry (Koethe et al., 2012). Proteomic anal-
ysis also showed that PRNT+ had higher levels of two other fac-
tors associated with signal transduction and viral entry. First,
there is CLEC4G (p = 0.017; Figure 4C), which is a glycan-bind-
ing receptor already described as acting as a recognition and up-
take molecule for multiple viruses, including SARS coronavi-
ruses (Gramberg et al., 2005). Second, there is fragment
crystallizable (Fc) receptor-like 6 (FCRL6) (p = 0.017; Figure 4D),
which can act as the major histocompatibility complex II recep-C
tor (MHC II) mediating virus entry
(Schreeder et al., 2010). Finally, correla-
tion analysis confirmed that SLAMF1
was positively associated with PRNT
(p = 0.001; Figure 4E), SARS-CoV-2 IgG
(p = 0.0003; Figure 4F), and Ag-specific
B cells (p = 0.028) (not shown). These
data collectively confirm a close relation
between cellular and neutralizing activity
in SARS-CoV-2 immunity.Multiomics factor analysis (MOFA)
revealing predictors of anti-SARS-
CoV-2 neutralization activity
To provide a comprehensive immuno-
logic description of patients with the
differential ability to produce neutral-
izing antibodies, we applied MOFA(Argelaguet et al., 2019). In this analysis, we used as input
phenotypic features describing T and B cells, Ag-specific
cell frequencies, and plasma proteins. We focused on the
top seven factors that were identified as major contributors
toward the neutralization activity (Figure 5A). Among those,
the plasma proteome did not show a relevant contribution
(factor 1 in Figures 5A and S5A). Conversely, factors 3 and
6, mainly driven by the frequencies of B and T cell
subsets, were able to discriminate between PRNT+ and
PRNT (Figure 5C). This analysis proved that resting memory
B cells (IgDCD27+CD21+) and activated memory B cells
(IgDCD27+CD21) in factor 3 (Figure 5C), along with acti-
vated T-Bet+ B cell subsets (Figure S5B) in factor 6, repre-
sented the main loading features for the identification of
PRNT+/PRNT groups. For the T cell subsets in factor 3, the
highest weight for group discrimination was mainly
provided by the frequency of central memory (CM), effector
memory (EM), and CD40L+ memory T cells (Figure 5D).
Overall, these data suggest that the development of NAbs is
favored by the presence of an intact memory B and T cell
compartment.ell Reports 34, 108852, March 16, 2021 5
Figure 4. Proteomic analysis revealing
distinct patterns in patients with differential
anti-SARS-CoV-2 Ab-neutralization activity
(A–D) Non-parametric Mann-Whitney test was
used to compare proteomics analysis of 7 PRNT,
21 PRNT, and 15 HC; means and SD are shown in
the plots.
(E and F) Correlation analysis between PRNT (E)
and SARS-CoV-2 IgG versus SLAMF1 (F, n = 28).
Non-parametric Spearman correlation test was
used in (E) and (F); solid lines define linear
regression, and grey area shows 95% confidence
interval.
Light purple solid circle, PRNT+; light green solid




This work provides a virological and immunological character-
ization of SARS-CoV-2-infected children presenting differential
Ab-mediated neutralizing activity. It further shows that children
with NAbs present a reduced viral load, faster virus clearance,
and lower in vitro infectivity. These data provide information
that can drive vaccination endpoints and quarantine measures
policies. In particular, we explored SARS-CoV-2-specific humor-
al and cellular responses in peripheral blood mononuclear cells
(PBMCs) and plasma collected 1 week after symptoms onset.
We correlated such results with a quantitative analysis of
SARS-CoV-2 viral load and in vitro infectivity. We stratified the
cohort according to humoral responses and found that the6 Cell Reports 34, 108852, March 16, 2021SARS-CoV-2 viral load was lower in indi-
viduals with both SARS-CoV-2 IgG and
PRNT, showing the impact of Ab-medi-
ated responses on the SARS-CoV-2 viral
load in NP in children. Confirming previ-
ous in vitro findings (Qin et al., 2020;Walls
et al., 2020), we showed that children pre-
senting higher anti-Spike protein IgG
levels and higher concentrations of
NAbs are the ones with lower viral bur-
dens and faster virus clearance. This in-
formation further confirms that pediatric
patients are able to mount a humoral
response relatively early after symptoms
onset (Yonker et al., 2020), which affects
both viral load and virus clearance.
Although there is as yet no consensus
that a higher viral load in NP correlates
with a higher infectivity of patients, here,
we show the impact of humoral immunity
on virus replication, in vitro infectivity,
and, presumably, virus spread. Hence,
SARS-CoV-2-infected children able
to mount in vitro neutralization could
benefit from less restrictive quarantine
measures.
Furthermore, we studied SARS-CoV-
2-specific cellular responses that arestill unknown in the pediatric setting. Recent works have
focused mainly on adult groups and demonstrated a clear as-
sociation between the presence of SARS-CoV-2 specific
CD4+ T cells and the development of effective neutralizing
activity (Grifoni et al., 2020; Weiskopf et al., 2020; Altmann
and Boyton, 2020; Rydyznski Moderbacher et al., 2020). In
the present study, we confirmed a positive association be-
tween humoral responses and SARS-CoV-2-specific CD4+
T cells in children. In particular, individuals with elevated levels
of SARS-CoV-2-specific CD4+ T cells also showed elevated
levels of effective neutralizing activity, associated with
reduced viral load. We further revealed that Ag-specific B cells
were positively associated with SARS-CoV-2 neutralization
activity and IgG titers. These results suggest Ag-specific
(legend on next page)






OPEN ACCESSB cell frequency as a cellular marker for Ab-mediated
neutralization.
We then moved on to explore whether neutralization activity
was associatedwith particular B and T cell phenotype character-
istics that could favor humoral responses in SARS-CoV-2-in-
fected children. Our data showed that neutralization activity
was associated with lower levels of exhausted B and T cell phe-
notypes. TLM B cell frequencies, previously shown to be higher
in chronic infections (Meffre et al., 2016; Moir et al., 2008), were
lower in PRNT+ patients. Accordingly, memory B cells were posi-
tively associated with both SARS-CoV-2 IgG and PRNT titers.
Therefore, these B cell phenotype characteristics can be useful
to estimate the ability of the patients to produce anti SARS-
CoV-2 humoral responses. Of note, these results are in line
with a recent report in adults showing that the majority (>90%)
of Ag-specific cells able to produce effective NAbs present a
memory phenotype (Seydoux et al., 2020). This observation
may further support the use of convalescent plasma containing
high doses of NAbs (Tonn et al., 2020), as in previous attempts
to support faster virus clearance in critical cases of COVID-19
(ClinicalTrials.gov: NCT04391101 and NCT04374370) (Li et al.,
2020; Valk et al., 2020).
The characterization of children with differential anti-SARS-
CoV-2 neutralizing activity was enriched by the analysis of
plasma proteomic profiling. We found that few proteins involved
in viral signal transduction were differentially expressed in
PRNT+ and PRNT. In particular, SLAMF1 and CD244 were
significantly higher in PRNT+ patients as compared to PRNT
patients. The reduction of these molecules in plasma may reflect
an intracellular consumption in a phase of higher viral load, such
as the one found in PRNT. These data support the idea that an
anti-SARS-CoV-2 immune response is being triggered in
PRNT. These molecules are crucial in activated lymphocytes
to transduce the signal of an MHC-processed antigen, such as
measles virus (Lin and Richardson, 2016). In line with this, Walls
et al. (2020) showed the homologous protein domains of mea-
sles virus and coronaviruses, including SARS-CoV-2. It was
recently argued that adaptive protection may be provided by
the measles, mumps, and rubella vaccine and bacille Calm-
ette-Guerin (BCG) (Mantovani and Netea, 2020; Sidiq et al.,
2020). Furthermore, CLEC4G, already described as acting as a
recognition and uptake molecule for multiple viruses, including
Ebola, West Nile, and SARS coronaviruses (Gramberg et al.,
2005), was found to be higher in PRNT+ compared to PRNT.
Overall, these data confirm the close relation between cellular
and humoral responses to control SARS-CoV-2 burden in
children.
From a clinical perspective, our cohort was characterized by
scarce symptoms variability, with the majority of children pre-
senting with mild symptoms, as also observed by others (Brodin,
2020). However, in accordance with other findings (WeisbergFigure 5. Multiomics factor analysis (MOFA) showing clusterization fa
(A) Fraction of variance explained by 7 latent factors is shown for 28 patients.
(B) Samples distributed across the top 6 latent factors.
(C and D) Top contributing features and loading direction (+ and ) for factor 3 in
AM, activatedmemory; CM, central memory; DN, double negative; EM, effectorm
TLM, tissue-like memory.
8 Cell Reports 34, 108852, March 16, 2021et al., 2021), we found no association between disease severity
and anti-SARS-CoV-2 Ab production. It is important to note that
the asymptomatic patients (n = 14) included in our cohort and the
11 multi-inflammatory syndrome associated with COVID-19
(MIS-C) patients, previously published (Consiglio et al., 2020),
showed no major differences in terms of SARS-CoV-2 serology
and neutralization activity compared to mild COVID-19 cases
(Consiglio et al., 2020). These data support the hypothesis that
inflammation dynamics rather than adaptive immunity orches-
trates the clinical course of the disease and specifically the
development of MIS-C. In line with this, plasma inflammation
markers were not able to discriminate between PRNT+ and
PRTN patients, supporting the hypothesis that the ability to
produce neutralizing antibodies does not directly associate
with grade of inflammation, but rather with the status of the im-
mune system.
This work provides a description of SARS-CoV-2-specific hu-
moral and cellular immunity in children and its relation to virus
load, virus clearance, and infectivity. Both Ag-specific T and B
cells positively correlate with anti-SARS-CoV-2 antibody titers
and neutralization activity, suggesting cell correlates of SARS-
CoV-2 immunity in this population. Public health restrictive mea-
sures should take into account such results to reconsider the
timing of confinement and NP retesting in pediatric patients pre-
senting strong humoral responses. Additional confirmatory
studies involving adult cohorts aswell as larger cohorts of children
with COVID-19 and with a higher symptom variability are needed.
Limitations of study
This study presents some limitations: (1) the small sample sizes
within each comparison; (2) the fact that these patients are from
one region reduces the ability to translate the impact of this infor-
mation on arising viral strains; (3) the lack of adjustment for mul-
tiple comparisons, as this was a descriptive study of a unique
cohort; and (4) the inability to accurately estimate timing of infec-
tion in asymptomatic patients.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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Antibodies
CD154-PE (CD40L, clone TRP1) BD Cat#555700; RRID: AB_396050
CD3PE-CF594 (clone UCHT1) BD Cat#562280; RRID: AB_11153674
CD4 BV510 (SK3) BD Cat#562970; RRID: AB_2744424
CD27 V450 (M-T271) BD Cat#561408; RRID: AB_10682577
CD45RO PE-Cy5 (UCHL1) Biolegend Cat#304208; RRID: AB_314424
CD185 BV605 (CXCR5, RF8B2) BD Cat#740379; RRID: AB_2740110
CD197 BV786 (CCR7, 3D12) Biolegend Cat#563710; RRID: NA
IL-21 APC (3A3-N2) Biolegend Cat#513008; RRID: AB_11150407
IL-2 PE-Cy7 (MQ1-17H12) Biolegend Cat#500326; RRID: NA
IFNg FITC BD Cat#552887; RRID: NA
TNFa AF700 (Mab11) Biolegend Cat#502928; RRID: NA
CD10 Pe-Cy7(HI10a) BD Cat#312214; RRID: AB_400216
CD19 APC-R700(SJ25C1) BD Cat#659121; RRID: AB_2870470
CD21 APC (B-Ly4) BD Cat#559867; RRID: AB_2085309
CD27 FITC(M-T271) BD Cat#555440; RRID: AB_395833
IgD BV421(IA6-2) BD Cat#565940; RRID: AB_2739404
IgM PE-CF594(G20-127) BD Cat#562539; RRID: AB_2737641
IgG BV605(G18-145) BD Cat#563246; RRID: AB_2738092
Double Strand RNA (dsRNA J2) Scicons J2 produced in mouse
Peroxidase-labeled goat anti-mouse Thermofisher Cat#G-21040
True Blue (KPL) SeraCare Cat#5510-0052
Biological samples
Peripheral venous EDTA blood OPBG n.a.
Swab-preserving media OPBG n.a.
Chemicals, peptides, and recombinant proteins
BD FACS Permeabilizing Solution 2 BD Cat# 347692
BD Golgi Stop BD Biosciences Cat#554724
Anti-CD28 (1 mg/ml) BD Cat#555725
Bovine Albumin Fraction V (7.5% solution) Thermofisher Cat#15260037
Dimethyl sulfoxide Sigma-Aldrich Cat#D8418
Dulbecco’s Phosphate buffered saline EuroClone Cat#ECB4004L
Fetal Bovine Serum GIBCO Cat#10270-106
Ficoll-Paque PLUS GE Healthcare Cat#17-1440-03
PepTivator SARS-CoV-2 Prot_S Miltenyi Biotec Cat#130-126-700
S1+S1 SARS-CoV-2 Prot S Sino Biological Cat# 40589-V08B1
RPMI 1640 EuroClone Cat#ECM9106L
Dulbecco’s modified Eagle’s medium GIBCO Cat#11995065
Triton X-100 Sigma Cat# T8787
Penicillin-Streptomycin Thermofisher Cat# 15140122
Paraformaldehyde (PFA) 4% solution Sigma Cat# 1004968350
Carbo xymethyl cellulose salt Sigma Cat# C5013-500G
MEM Thermofisher Cat# 11095080
Tween-80 Sigma Cat#P1754
(Continued on next page)
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Critical commercial assays
Live/dead Fixable Near-IR Dead cell Stain
kit
Invitrogen Cat#L34976
Lightning-Link R-PE Conjugation Kit (Innova Biosciences) Cat#703-0030
Deposited data
Full datasets Mendeley http://doi.org/10.17632/stxwzbyfsc.1
Experimental models: cell lines
Vero E6 cells ATCC CRL 1586
Oligonucleotides
Primers for SARS-CoV-2 E gene: forward
ACAGGTACGTTAATAGTTAATAGCGT
Corman et al., 2020 N/A
Primers for SARS-CoV-2 E gene: reverse
ATATTGCAGCAGTACGCACACA




Corman et al., 2020 N/A
Housekeeping GAPDH PE Applied Biosystems Cat#402869
GAPDH Kit (PE Applied Biosystems) N/A N/A
Software and algorithms
Kaluza software Beckman Coulter https://www.beckman.com/
flow-cytometry/software/kaluza?
country=US




R scripts to reproduce the analyses GitHub https://github.com/GRP92/
PRNT_manuscript
Other
Droplet Generation Oil for Probes Bio-Rad Cat#1863005
One-Step RT-ddPCR Adv Kit Bio-Rad Cat#1864022
QX200TM Droplet Generator Bio-Rad Cat#1864002
96 well plate Bio-Rad Cat#HSS9641
Eppendorf Mastercycler Eppendorf Cat#6313000018
QX200TM Droplet Reader Bio-Rad Cat#1864003





Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dr. Paolo
Palma (paolo.palma@opbg.net).
Materials availability
No new reagents were developed during the study. Patient samples can be made available within the limits of the approved Ethical
permits. Such requests should be directed to the lead contact author.
Data and code availability
The published article includes all dataset generated or analyzed during this study.
Scripts to reproduce the analyses presented in each figure of the paper are available at https://github.com/GRP92/
PRNT_manuscript. Full datasets are available at https://data.mendeley.com/datasets/stxwzbyfsc/1.e2 Cell Reports 34, 108852, March 16, 2021
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OPEN ACCESSEXPERIMENTAL MODEL AND SUBJECT DETAILS
Study participants
Sixty six SARS-CoV-2 infected children (SARS-CoV-2 +) (see Table 1) and 11 SARS-CoV-2 negative controls (SARS-CoV-2 neg) were
enrolled in the CACTUS (Immunological studies in Children AffeCTed by COVID and acUte reSpiratory diseases) study fromMarch to
April 2020 at Bambino Gesù Children’s Hospital in Rome (see Table S2). Local ethical committee approved the study and written
informed consent was obtained from all participants or legal guardians. Age, gender, clinical and routine laboratory characteristics of
the cohort are described in Table 1. SARS-CoV-2 + were patients tested positive for SARS-CoV-2 real-time reverse transcriptase–
polymerase chain reaction (RT-PCR) tests (GeneXpert, Cepheid, Sunnyvale, CA; 250 copies/mL sensitivity, 100% specificity) in
nasopharingeal swab (NP).SARS-CoV-2+werestratifiedaccording topresence (PRNT+)orabsence (PRNT-) of neutralizingantibodies.
Controls enrolled in the studies (SARS-CoV-2 neg)were children admitted to our hospital with suspected SARS-CoV-2 infection, due to
fever or respiratory symptoms, but tested negative for 2 consecutive nasopharyngeal swabs (performed 24 hours apart) and for SARS-
CoV-2 S1/S2 IgG test. Longitudinal blood samples were collected at admission, after 48 hours and approximately 7 days after admis-
sion. Viral load in NPwas performed in SARS-CoV-2 + every 48 hours up to undetectable viral load. Patients with clinical records of pri-
mary or acquired immune compromising conditions, recent or current administration of immune suppressive therapies, or other dis-
eases affecting the immune system were excluded from the study. Duration of symptoms was calculated as the number of days
between symptoms onset and date of analysis; for asymptomatic patients, the symptom onset of the family member or direct contact
who resulted positive for SARS-CoV-2 was used. A control group of age, gender and ethnicity individuals (N = 12) was included to
analyze the T cell phenotype. A previously described control group was used for proteomic analysis (Consiglio et al., 2020).
METHOD DETAILS
Sample collection and storage
Venous blood was collected in EDTA tubes and processed within 2 hours. Plasma was isolated from blood and stored at 80C.
Peripheral blood mononuclear cells (PBMCs) were isolated from blood of all patients with Ficoll density gradient and cryopreserved
in FBS 10% DMSO until analysis, in liquid nitrogen. Nasopharyngeal swab preserving media was stored at 80C until use.
Detection and quantification of SARS-CoV-2 RNA in nasopharyngeal swab (NP)
SARS-CoV-2 viral load was evaluated using both RT-PCR and ddPCR. For the RT-PCR, the qualitative SARS-CoV-2 real-time
reverse transcriptase–polymerase chain reaction (RT-PCR) tests was used according to manufacturer instruction (Seegene’s Allplex
2019-nCoV Assay, Republic of Korea). The assay is designed to allow for detection of both E and RdRp genes, which showed com-
parable specificity for SARS-CoV-2 (Corman et al., 2020). The system is designed to provide an auto-interpretation of the data along-
side a Ct value resulting from the amplification of each gene.
An in-housemultiplex quantitative assay based onOne-Step RT- digital droplet (dd) PCRwas used to quantitate SARS-CoV-2 viral
load. Total RNAwas isolated fromNP preservingmedia and eluted in a final volume of 100 ml. The reactionmixture consisted of 5 ul of
supermix (Bio-Rad, CA, USA), 2 mL of reverse transcriptase; 2 mL of DTT final concentration 300mM; forward and reverse primers of
SARS-CoV-2 E gene to a final concentration of 400 nM each and probe to a final concentration of 200 nM (Corman et al., 2020) and
5 mL of nucleic acids eluted from nasapharyngeal swab samples into a final volume of 20 ml. Housekeeping GAPDH, employed to
control the quality of extracted RNA, was amplified under the same conditions using the GAPDH Kit (PE Applied Biosystems);
5 mL of nucleic acids eluted from nasapharyngeal swab samples into a final volume of 20 ml. Each well of the preparedmix was loaded
into the 8-channel cartridge to generate the droplets in the oil suspension according tomanufacturer (Bio-Rad). Reverse transcription
and PCR cycles were run as follow: reverse transcription at 42-50C for 60 min; enzyme activation at 95C for 10min; denaturation of
cDNA at 95C for 30sec and annealing/extension at 60C for 1 min; these last two passages were repeated for 40 cycles followed by
enzyme deactivation at 98C for 10 min. The droplets were then read by the QX200TM Droplet Reader (Bio-Rad) and the results were
analyzedwith theQuantaSoftTM Analysis Software 1.7.4.0917 (Bio-Rad).Wells with less than 10000 droplets were discarded from the
analysis. Each sample was run at least in duplicate. The final results were expressed as SARS-CoV-2 copies/5 ml. We compared the
results obtained by both ddPCR and RT-PCR and we found a significant inverse linear correlation between the Ct values of RT-PCR
and the viral copy number provided by the ddPCR (r =0.906, p < 0.0001). The derived formula y =3.40 x+ 36.88 was employed to
convert the Ct values in viral copies for samples tested only by RT-PCR.
AUC
The SARS-CoV-2 viral load measurements for the gene E in NP were used to calculate the AUC as follow. The viral load was calcu-
lated at multiple time points to calculate the area under the curve for each patient. The curves were drawn plotting on the y axis the
viral copies and on the x axis the number of days between the date of swab collection and the date of onset of symptoms for symp-
tomatic patients and the hospital admission date for non-symptomatic ones. The average value was considered for the association
with PRNT and SARS-CoV-2 IgG.Cell Reports 34, 108852, March 16, 2021 e3
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Vero E6 cells (ATCC CRL 1586) were cultured in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO) supplemented with 10%
FBS, penicillin (100 U/ml) and streptomycin (100U/ml), at 37C in a humidified CO2 incubator. To titrate virus infectivity, nasopharyn-
geal swab preserving media was filtered through a 0.22 mm filter and serially diluted in DMEM supplemented with 2% FBS, penicillin
(100 U/ml) and streptomycin (100U/ml). Dilutions were incubated on confluent monolayers of Vero E6 cells, in 96-well plates, for 1
hour. After infection, the inoculum was removed and an overlay of MEM, 2% FBS, penicillin (100 U/ml) and streptomycin (100U/
ml) and 0.8% carboxymethyl cellulose was added. After 27 hours, the overlay medium was removed and cells were fixed in PBS
4% PFA, for 30 minutes at 4C. Upon removal, cells were permeabilized with a 0.5% Triton X-100 solution for 10 minutes. Immuno-
staining was performed by incubation of the J2 anti-dsRNA monoclonal antibody (1:10,000; Scicons) for 1 hour, followed by incuba-
tion with peroxidase-labeled goat anti-mouse antibodies (1:1000; DAKO) for 1 hour and a 7 min incubation with the True Blue (KPL)
peroxidase substrate. Immuno-reagents were prepared in a solution of 1% BSA and 0.05% Tween-80 in PBS. After each antibody
incubation, cells were washed 4 times with a 0.05% Tween-80 PBS solution. Focus forming units per ml (FFU/ml) were counted after
acquisition of pictures at a high resolution of 4800 3 9400dpi, on a flatbed scanner.
Plaque reduction neutralization test (PRNT)
A high- throughput PRNTmethod was developed in-house. Briefly, plasma samples were heat- inactivated by incubation at 56C for
30 minutes and 2-fold dilutions were prepared in Dulbecco modified Eagle medium (DMEM). The dilutions were mixed to a 1:1 ratio
with a virus solution containing 20-25 FFUs of SARS-CoV-2 and incubated for 1 hour at 37C. Fifty microliters of the virus–serum
mixtures were added to confluent monolayers of Vero E6 cells, in 96-wells plates and incubated for 1 hour at 37C, in a 5%CO2 incu-
bator. The inoculumwas removed and 100 mL of overlay solution of Minimum essential medium (MEM), 2% fetal bovine serum (FBS),
penicillin (100 U/ml), streptomycin (100 U/ml) and 0.8% carboxy methyl cellulose was added to each well. After 26 hours’ incubation,
cells were fixed with a 4% paraformaldehyde (PFA) solution. Visualization of plaques was obtained with an immunocytochemical
staining method using an anti-dsRNA monoclonal antibody (J2, 1:10,000; Scicons) for 1 hour, followed by 1-hour incubation with
peroxidase-labeled goat anti-mouse antibodies (1:1000; DAKO) and a 7-minute incubation with the True BlueTM (KPL) peroxidase
substrate. FFUswere counted as described above. The serum neutralization titer was defined as the reciprocal of the highest dilution
resulting in a reduction of the control plaque count > 50% (PRNT50). We considered a titer of 1:10 as the seropositive threshold.
Generation of SARS-CoV-2 probe to select B cells antigen-specific cells
The S1+S2 Spike SARS-CoV-2 protein was obtained from MyBiosource and labeled with Lightning-Link R-PE Conjugation Kit (In-
nova Biosciences) to obtain a SARS-CoV-2-R-PE.
Ag-specific B cells by flow cytometry
PBMCs underwent surface staining for the B cell phenotype with the following antibodies: CD10 Pe-Cy7(HI10a) from Biolegend,
CD19 APC-R700(SJ25C1), CD21 APC(B-Ly4), CD27 FITC(M-T271), IgD BV421(IA6-2), IgM PE-CF594(G20-127), IgG BV605(G18-
145) fromBD, S1+S2 Sars-CoV-2-R-Phycoerythrin (-R-PE) and Live/Dead (BV510; BD). Following fixing and permeabilization of cells
(BD permeabilization solution II 1x), cells were stained with an anti T-bet BV650 (04-46, BD). Cells were acquired using Cytoflex
(Beckman Coulter, Brea, CA). Gating strategies are provided in Figure S2. Positive cell gating was set using fluorescence minus
one control. Data analyses were performed using Kaluza software (Beckman Coulter).
CD4 Ag-specific T cells by flow cytometry
Thawed PBMC were plated (1.5x106/aliquot/200 ul) in 96 well-plate containing CD154-PE (CD40L, BD PharMingen, Franklin Lakes,
NJ, USA), Golgi Stop (SigmaAldrich), anti-CD28 (1 mg/ml) and either 0,4mg/ml PepTivator SARS-CoV-2 Prot_S (Milteny Biotech, Ber-
gisch Gladbach, Germany) or media only. Following 16hrs incubation at 37C/5% CO2, PBMC were centrifuged and stained with
LIVE/DEAD fixable NEAR-IR dead cell stain kit (for 633 or 635 nm excitation, ThermoFisher, Waltham, Massachusetts, US) 1ul per
106cells/ml for 15minutes at room temperature (RT), protected by light. Antigen specific CD40L+CD4+ T cells were identified accord-
ing to the gating strategy showed in Figure 3A. Preliminary experiments on unstimulated (UN), SARS-CoV-2 stimulated (STIM), or
SEB-stimulated (not shown) healthy controls collected in the pre-COVID-19 era were used to set the gate. Following in vitro stimu-
lation with SARS-CoV-2 antigens, only SARS-CoV-2 + patients showed increase in CD40L+ T cells demonstrating the antigen-spe-
cific cellular response (Figure S3A). Surface staining was performed using the following antibodies: CD3 PE-CF594 (UCHT1), CD4
BV510 (SK3), CD27 V450 (M-T271), CD45RO PE-Cy5 (UCHL1), CD185 BV605 (CXCR5, RF8B2) from BD (USA); CD197 BV786
(CCR7, 3D12), from Biolegend (San Diego, CA, USA). Intra-cytokines staining (ICS) was performed following permeabilization using
BD Perm sol II 1X (BD) and included IFNg FITC, fromBD; TNFa AF700 (Mab11), IL-2 PE-Cy7 (MQ1-17H12), IL-21 APC (3A3-N2), from
Biolegend. Gating strategy for T cell phenotype is provided in Figure S3.
Serum protein profiling
Serum proteins were analyzed using a multiplex technology based upon proximity-extension assays (Lundberg et al., 2011). Briefly,
each kit consisted of a microtiter plate for measuring 92 protein biomarkers in all 88 samples and each well contained 96 pairs of
DNA-labeled antibody probes. To minimize inter- and intra-run variation, the data were normalized using both an internal controle4 Cell Reports 34, 108852, March 16, 2021
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OPEN ACCESS(extension control) and an interplate control, and then transformed using a pre-determined correction factor. The pre-processed data
were provided in the arbitrary unit Normalized Protein Expression (NPX) on a log2 scale andwhere a high NPX represents high protein
concentration.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, Inc., San Diego, CA) and R software (version
3.6.2). Statistical significance was set at p < 0.05 and the test were two-tailed. All data were analyzed D’Agostino-Pearson to assess
normality. For non-parametric or parametric data, median or mean are presented, respectively and Mann-Whitney non-parametric
test or t test were used for the comparisons, as indicated in figure legends. Chi-square test was used for gender analysis. The AUC
values were calculated with the MESS package (version 0.5.6) as described above. Spearman’s correlation was used to examine the
association between features. In correlation heatmaps only statistically significant correlations were shown. Linear univariate regres-
sion analysis were performed with the ‘‘lm’’ function (stats R package version 3.6.2). MOFAwas performed with the MOFA2 package
(version 1.0) in the R statistical environment (Argelaguet et al., 2019). Graphpad Prism 8 software was used for statistical analysis (of
the cells type distribution and serological parameters) for demographic and routine laboratory blood tests.Cell Reports 34, 108852, March 16, 2021 e5
